Review Article
Treatment for Recurrent Ovarian Cancer—At First Relapse
Table 4
Study result for platinum resistant recurrent ovarian cancer (single agent).
| | PLD | GEM | Topotecan | PLD versus | PLO versus GEM | | | | | Topotecan | |
| Dose | 50 mg//4w | 1 g/ | 1.5 mg/ d1–5/3w | 50 mg//4w | 50 mg//4w |
| | | d1.8.15/4w | (1 mg//3w) | 1.5 mg/ for 5 d/3w | 19/d1.8/3w | | | | | | | Author | Gordon et al. [31] | Markman [11] | Bookman et al. [15] | O’Malley et al. [13] | Mutch et al. [14] | | | | (Rodriguez et al. [36]) | | | | | | | | | Number of patients | 82 | 51 | 112 (37) | 130 versus 124 | 96 versus 99 | Response rate | | | | | | CR PR (%) | 18.3 | 16 | 12.4 (22 ) | 12.3 versus 6.5 | 8.3 versus 6.1 | SD (%) | 66.1 | NA | NA(44) | 40 versus 49.2 | 46.9 versus 60.6 | | | | | | | Most frequent | | | | | | Adverse effect | PPE | neutropenia | neutropenia | PPE/neutropenia | fatigue/fatigue | PFS (weeks) | 17 | 16 | 12.1 (18) | 9.1 versus 13.6 | 12.4 versus 14.4 | OS (weeks) | | 15 (months) | 47 (NA) | 35.6 versus 41.3 | 50.8 versus 54 |
|
|
PPE: palmar-plantar erythrodysesthesia.
|